Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Betulinic acid (high purity)

Antitumor and anti-HIV agent
 
ALX-350-277-M005 5 mg 36.00 USD
 
ALX-350-277-M025 25 mg 111.00 USD
 
ALX-350-277-M100 100 mg 349.00 USD
Do you need bulk/larger quantities?
 
Replaces Prod. #: BML-AP301

Antitumor and anti-HIV agent. Induces apoptosis by activating mitochondrial permeability transition (MPT). Inhibits NF-κB activation and NF-κB-regulated gene expression induced by carcinogens and inflammatory stimuli. Decreases expression of Bcl-2 and cyclin D1. Potent proteasome activator. Triggers CD95- and p53-independent apoptosis via activation of caspases. It induces mitochondrial permeability pore opening and the release of cytochrome c and apoptosis-inducing factor. Displays anti-HIV activity. EC50 for inhibion of HIV-1 replicaton in H9 lymphocytes: 1.4µM.

Product Specification

Alternative Name:3β-Hydroxy-20(29)-lupaene-28-oic acid
 
Formula:C30H48O3
 
MW:456.7
 
Source:Isolated from Platanus acerifolia (plane) tree bark.
 
CAS:472-15-1
 
Purity:≥97% (HPLC)
 
Appearance:White to off-white powder.
 
Solubility:Soluble in DMSO.
 
Shipping:Ambient
 
Long Term Storage:+4°C
 
Handling:Keep cool and dry.
 
350-277
Please mouse over
350-277

Product Literature References

Activation and inhibition of the proteasome by betulinic acid and its derivatives: L. Huang, et al.; FEBS Lett. 581, 4955 (2007), Abstract;
Betulinic acid and its derivatives, potent DNA topoisomerase II inhibitors, from the bark of Bischofia javanica: S. Wada & R. Tanaka; Chem. Biodivers. 2, 689 (2005), Abstract;
Betulinic acid and its derivatives: a review on their biological properties: P. Yogeeswari and D. Sriram; Curr. Med. Chem. 12, 657 (2005), Review, Abstract;
Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy: H. Kasperczyk, et al.; Oncogene 24, 6945 (2005), Abstract; Full Text
Induction of central signalling pathways and select functional effects in human platelets by beta-boswellic acid: D. Poeckel, et al.; Br. J. Pharmacol. 146, 514 (2005), Abstract;
Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo: T. Syrovets, et al.; J. Biol. Chem. 280, 6170 (2005), Abstract;
Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection: R.H. Cichewicz & S.A. Kouzi; Med. Res. Rev. 24, 90 (2004), Abstract;
Betulinic acid suppresses carcinogen-induced NF-kappa B activation through inhibition of I kappa B alpha kinase and p65 phosphorylation: abrogation of cyclooxygenase-2 and matrix metalloprotease-9: Y. Takada & B.B. Aggarwal; J. Immunol. 171, 3278 (2003), Abstract;
Effects of betulinic acid alone and in combination with irradiation in human melanoma cells: E. Selzer, et al.; J. Invest. Dermatol. 114, 935 (2000), Abstract;
Betulinic acid-induced apoptosis in glioma cells: A sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing: W. Wick, et al.; J Pharmacol. Exp. Ther. 289, 1306 (1999), Abstract; Full Text
Betulinic acid: a new cytotoxic agent against malignant brain-tumor cells: S. Fulda, et al.; Int. J. Cancer 82, 435 (1999), Abstract;
Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid: S. Fulda, et al.; J. Biol. Chem. 273, 33942 (1998), Abstract; Full Text
Betulinic acid inhibits aminopeptidase N activity: M.F. Melzig & H. Bormann; Planta Med. 64, 655 (1998), Abstract;
Correspondence re: S. Fulda et al., Betulinic acid triggers CD95 (Apo1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res., 57: 4956, 1997: M. Rieber & M. Strasberg Rieber; Cancer Res. 58, 5876 (1998), Abstract;
Induction of p53 without increase in p21WAF1 in betulinic acid-mediated cell death is preferential for human metastatic melanoma: M. Rieber & M. Strasberg Rieber; DNA Cell Biol. 17, 399 (1998), Abstract;
Anti-AIDS agents--XXVII. Synthesis and anti-HIV activity of betulinic acid and dihydrobetulinic acid derivatives: F. Hashimoto, et al.; Bioorg. Med. Chem. 5, 2133 (1997), Abstract;
Betulinic acid induces apoptosis in human neuroblastoma cell lines: M.L. Schmidt, et al.; Eur. J. Cancer 33, 2007 (1997), Abstract;
Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors: S. Fulda, et al.; Cancer Res. 57, 4956 (1997), Abstract;
Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents: Y. Kashiwada, et al.; J. Med. Chem. 39, 1016 (1996), Abstract;
Chemotherapy of human immunodeficiency virus (HIV) infection: anti-HIV agents targeted at early stages in the virus replicative cycle: E. De Clerq; Biomed. Pharmacother. 50, 207 (1996), Abstract;
Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis: E. Pisha, et al.; Nat. Med. 1, 1046 (1995), Abstract;
Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids: T. Fujioka, et al.; J. Nat. Prod. 57, 243 (1994), Abstract;

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,